Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Glatman-Freedman, Aharona ; Bromberg, Michal ; Hershkovitz, Yael ; Sefty, Hanna ; Kaufman, Zalman ; Dichtiar, Rita ; Keinan-Boker, Lital
• Description:
  We estimated vaccine effectiveness (VE) of the BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) booster dose against SARS-CoV-2 infection and reduction of complications (hospitalization, severe disease, and death) among breakthrough cases in persons in Israel >16 years of age for <20 weeks. VE estimates reached 96.8% (95% CI 96.0%-97.5%) for persons 16-59 years of age and 93.1% (95% CI 91.8%-94.2%) for persons >60 years of age on week 3. VE estimates remained at these levels for 8 weeks in the 16-59 age group and 11 weeks in those >60. A slow decline followed, becoming more pronounced in the last 2-3 weeks of evaluation. Estimates in the last week of evaluation were 77.6% (95% CI 68.4%-84.2%) and 61.3% (52.5%-68.4%) for persons 16-59 years and >60 years, respectively. The more pronounced VE decline coincided with rapid increase in Omicron variant activity. Rate reduction of breakthrough complications remained moderate to high throughout the evaluation.
• Subjects:
  Aged, 80 And Over Bnt162 Vaccine Covid-19 Covid-19 Vaccines Humans Infant Sars-Cov-2
• Source:
  Emerg Infect Dis. 2022; 28(5):948-956
• Pubmed ID:
  35361311
• Pubmed Central ID:
  PMC9045419
• Document Type:
  Journal Article
• Place as Subject:
  Israel
• Volume:
  28
• Issue:
  5
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:b28fd721c0b9db4c7520728687153ccd8df8a2c0d66c487441c66c408aae566e
• Download URL:
  https://stacks.cdc.gov/view/cdc/117303/cdc_117303_DS1.pdf
• File Type:
  [PDF - 1.27 MB ]